{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:10:33Z","timestamp":1769202633017,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.cgh.2009.03.015","type":"journal-article","created":{"date-parts":[[2009,3,23]],"date-time":"2009-03-23T10:59:36Z","timestamp":1237805976000},"page":"725-735.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice"],"prefix":"10.1016","volume":"7","author":[{"given":"Gaurav","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurkirpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Triadafilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2009.03.015_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.41.4.425","article-title":"The aging stomach: implications for NSAID gastropathy","volume":"41","author":"Lee","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2009.03.015_bib2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.163.2.169","article-title":"Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium","volume":"163","author":"Case","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/ard.2003.020313","article-title":"Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis","volume":"63","author":"Pincus","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2009.03.015_bib5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X","article-title":"A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee","volume":"44","author":"Pincus","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.cgh.2009.03.015_bib6","first-page":"12","article-title":"Identification of patients at risk for gastropathy associated with NSAID use","volume":"20","author":"Fries","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2009.03.015_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02599040","article-title":"Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs","volume":"11","author":"Smalley","year":"1996","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004836-199310000-00014","article-title":"NSAID-induced gastroduodenal damage: is prevention needed?","volume":"17","author":"Stalnikowicz","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2036.2003.01454.x","article-title":"Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors","volume":"17","author":"Micklewright","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Garcia Rodriguez","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2009.03.015_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-114-4-257","article-title":"Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons","volume":"114","author":"Griffin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib14","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"Henry","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","article-title":"Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Langman","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2009.03.015_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib17","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study","volume":"156","author":"Singh","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","article-title":"Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s","volume":"160","author":"Hernandez-Diaz","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00002018-200528040-00002","article-title":"NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management","volume":"28","author":"Chan","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2009.03.015_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib21","article-title":"Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID: results from a randomized, double-blind, controlled trial","author":"Goldstein","year":"2003","journal-title":"American College of Rheumatology Annual Meeting [Poster LB14\/523]"},{"key":"10.1016\/j.cgh.2009.03.015_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archinte.1994.00420010064008","article-title":"Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage","volume":"154","author":"Wilcox","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10620-005-1281-1","article-title":"Endoscopy in asymptomatic minidose aspirin consumers","volume":"50","author":"Niv","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2009.03.015_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","article-title":"Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding","volume":"343","author":"Lanas","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2036.2003.01550.x","article-title":"A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole","volume":"17","author":"Labenz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib28","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2009.03.015_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/00365529609010347","article-title":"Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study","volume":"31","author":"Ekstr\u00f6m","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2036.1998.00288.x","article-title":"Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users","volume":"12","author":"Cullen","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib31","first-page":"43","article-title":"Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study","volume":"30","author":"Bianchi Porro","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2009.03.015_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1590-8658(00)80821-X","article-title":"Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study","volume":"32","author":"Bianchi Porro","year":"2000","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2009.03.015_bib33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1365-2036.2000.00804.x","article-title":"Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects","volume":"14","author":"Pilotto","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000075926","article-title":"Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients","volume":"68","author":"Stupnicki","year":"2003","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2009.03.015_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","article-title":"Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors","volume":"101","author":"Scheiman","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1572-0241.2006.00686.x","article-title":"Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole","volume":"101","author":"Regula","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib37","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/j.1572-0241.2008.01995.x","article-title":"Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin","volume":"103","author":"Yeomans","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2036.2004.02246.x","article-title":"Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin\/non-steroidal anti-inflammatory drugs","volume":"20","author":"Pilotto","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib39","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2207","article-title":"Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study","volume":"9","author":"Vonkeman","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","article-title":"Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole","volume":"162","author":"Graham","year":"2002","journal-title":"Arch Intern Med"},{"issue":"Suppl III","key":"10.1016\/j.cgh.2009.03.015_bib43","first-page":"A82","article-title":"Efficacy of pantoprazole as compared to omeprazole and misoprostol in NSAID associated gastric ulcer","volume":"47","author":"Olteanu","year":"2000","journal-title":"Gut"},{"issue":"Suppl III","key":"10.1016\/j.cgh.2009.03.015_bib44","first-page":"A84","article-title":"The frequency of relapse and bleeding of previous gastroduodenal lesions in NSAID-users on maintenance treatment","volume":"47","author":"Kujundzic","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2009.03.015_bib45","doi-asserted-by":"crossref","first-page":"A892","DOI":"10.1016\/S0016-5085(00)85703-0","article-title":"A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDS","volume":"118","author":"Jensen","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2009.03.015_bib46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen","volume":"344","author":"Chan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2007.06.058","article-title":"Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs","volume":"133","author":"Ray","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2009.03.015_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","article-title":"Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial","volume":"127","author":"Chan","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2009.03.015_bib50","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.amjmed.2005.04.031","article-title":"Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications","volume":"118","author":"Lai","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib52","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","article-title":"Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial","volume":"369","author":"Chan","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2009.03.015_bib53","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1572-0241.2005.41465.x","article-title":"Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors","volume":"100","author":"Hawkey","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ageing\/afm049","article-title":"Prevention of NSAID gastropathy in elderly patients: an observational study in general practice and nursing homes","volume":"36","author":"van Leen","year":"2007","journal-title":"Age Ageing"},{"issue":"448","key":"10.1016\/j.cgh.2009.03.015_bib55","first-page":"427","article-title":"Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis","volume":"119","author":"Spiegel","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2006.02759.x","article-title":"Upper gastrointestinal bleeding associated with antiplatelet drugs","volume":"23","author":"Ibanez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1515\/DMDI.1998.14.3.193","article-title":"Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers","volume":"14","author":"van Hecken","year":"1998","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.cgh.2009.03.015_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1503\/cmaj.070186","article-title":"Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding","volume":"177","author":"Delaney","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib59","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib61","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cgh.2006.04.019","article-title":"Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications","volume":"4","author":"Lai","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2009.03.015_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.2004.01857.x","article-title":"Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers\/erosions with low to moderate bleeding\/re-bleeding risk: a single-blind, randomized controlled study","volume":"19","author":"Ng","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib63","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cgh.2009.03.015_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2036.1994.tb00281.x","article-title":"Rapid healing of gastric ulcers with lansoprazole","volume":"8","author":"Bardhan","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib67","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archinte.160.10.1455","article-title":"Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study\u2014NSAID-Associated Gastric Ulcer Study Group","volume":"160","author":"Agrawal","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.1998.00312.x","article-title":"Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer","volume":"12","author":"Bianchi Porro","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.1998.00331.x","article-title":"Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs","volume":"12","author":"Massimo Claar","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib70","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2036.2007.03460.x","article-title":"Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy: a randomized study comparing ranitidine with esomeprazole","volume":"26","author":"Goldstein","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib71","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1111\/j.1572-0241.2005.00243.x","article-title":"Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial","volume":"100","author":"Goldstein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib72","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1742-1241.2006.01147.x","article-title":"Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?","volume":"60","author":"Yeomans","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cgh.2009.03.015_bib73","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1572-0241.1998.00588.x","article-title":"A guideline for the treatment and prevention of NSAID-induced ulcers: members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology","volume":"93","author":"Lanza","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib74","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1572-0241.2005.41833.x","article-title":"A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use","volume":"100","author":"Lanas","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib75","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study\u2014a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2009.03.015_bib76","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-114-9-735","article-title":"Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs","volume":"114","author":"Piper","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib78","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/ard.2003.015925","article-title":"Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach","volume":"63","author":"Richy","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2009.03.015_bib79","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/BF02064210","article-title":"Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one year study","volume":"40","author":"Agrawal","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2009.03.015_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2036.2001.00890.x","article-title":"Randomized trial of low-dose misoprostol and naproxen vs nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs","volume":"15","author":"Chan","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib81","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-123-5-199509010-00004","article-title":"Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens","volume":"123","author":"Raskin","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/bmj.297.6655.1017","article-title":"Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine","volume":"297","author":"Ehsanullah","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib83","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/archinte.1993.00410210073008","article-title":"Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs","volume":"153","author":"Levine","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/00365529409091417","article-title":"Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients","volume":"206","author":"Simon","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2009.03.015_bib85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000199896","article-title":"Effect of ranitidine on gastroduodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugs","volume":"44","author":"Swift","year":"1989","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2009.03.015_bib86","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","article-title":"Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs","volume":"334","author":"Taha","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib87","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archinte.168.15.1684","article-title":"Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention","volume":"168","author":"Saini","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib88","doi-asserted-by":"crossref","DOI":"10.3310\/hta10380","article-title":"A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling","volume":"10","author":"Brown","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cgh.2009.03.015_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.21065","article-title":"Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups","volume":"53","author":"Spiegel","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2009.03.015_bib90","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1345\/aph.1G493","article-title":"Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs","volume":"40","author":"Hur","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cgh.2009.03.015_bib91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00296-003-0392-2","article-title":"Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis","volume":"25","author":"Yun","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cgh.2009.03.015_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-200363010-00006","article-title":"Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 4","key":"10.1016\/j.cgh.2009.03.015_bib94","first-page":"A138","article-title":"Tolerability and safety profile of pantoprazole based on 100,134 patients: results of a German post-marketing surveillance (PMS) program","volume":"112","author":"Hahn","year":"1997","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"10.1016\/j.cgh.2009.03.015_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2036.1999.00034.x","article-title":"Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy","volume":"13","author":"Lew","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2009.03.015_bib96","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1358\/dot.1999.35.10.561695","article-title":"Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man","volume":"35","author":"Radhofer-Welte","year":"1999","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.cgh.2009.03.015_bib97","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1503\/cmaj.1040876","article-title":"Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies","volume":"171","author":"Dial","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.cgh.2009.03.015_bib98","first-page":"500","article-title":"Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy","volume":"99","author":"Akhtar","year":"2007","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.cgh.2009.03.015_bib99","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2009.03.015_bib100","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/521664","article-title":"Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit","volume":"28","author":"Beaulieu","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cgh.2009.03.015_bib101","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2007.09.010","article-title":"Use of acid-suppressing drugs and the risk of bacterial gastroenteritis","volume":"5","author":"Garcia Rodriguez","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2009.03.015_bib102","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors","volume":"28","author":"Kaye","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cgh.2009.03.015_bib103","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2009.03.015_bib104","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2009.03.015_bib105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2007.03358.x","article-title":"Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage","volume":"26","author":"van Soest","year":"2007","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356509002304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356509002304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:04:00Z","timestamp":1761541440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356509002304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1542356509002304"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2009.03.015","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2009.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}